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2Agenda
? Influenza and the performance of TIV (2007-
2008)
? Approaches to improve influenza vaccine
? FluBlok: rHA produced in insect cells
? Safety, immunogenicity and efficacy results 
from four studies performed in different 
populations
3Influenza (the “Flu”)
? Contagious disease caused by the influenza virus
? Attacks the respiratory tract (nose, throat, lungs)
? “Flu-like Symptoms”
? Fever, Headache, Tiredness, Dry Cough, Sore Throat, Nasal 
Congestion, Body Aches
? Average “Flu” Season - November to April
? Most people recover in one to two weeks
? Complications from influenza
? Pneumonia, bronchitis, sinus and ear infections
? Individuals at high-risk for complications
? 65 and older
? Chronic heart or lung conditions
? Very young children
4Severity of Influenza
? 10-20% of the U.S. population gets influenza each year
? Influenza kills ~36,000 people per year in U.S.
? 21,000 more than from HIV-related illnesses
? >200,000 hospitalized per year with the “Flu”
5The Influenza Viruses
? Orthomyxoviruses (Greek, myxa=mucus)
? Three types of influenza virus (A, B, and C)
? A viruses
? Divided into subtypes based on genetic and antigenic differences 
among surface proteins (HA & NA)
? Current subtypes found in people are A(H1N1) and A(H3N2)
? B viruses
? No subtypes
? C viruses
? Cause mild respiratory illness
? Antigenic “Drift” of A and B viruses leads to epidemics 
every winter 
? Antigenic “Shift” of A viruses leads to pandemics
? 3x in the past 100 years 
6Licensed influenza vaccine
Production process:
Chicken Embryo’s
Isolation of Virus
Kill Virus
Isolate virus proteins
Long production cycle
One egg = one dose
Production affected by 
Avian influenza outbreaks
Adaptation required
Adverse reactions
Less effective in the elderly
Characteristics
Trivalent vaccine: 2 A strains and 1 B strain
Protection correlates with hemagglutinin (HA) antibodies
7Total duration of manufacturing 
process: 6 months
Regulatory controls
Review license amendments, ensure quality
Egg-based manufacturing is lengthy and inflexible
Egg 
supply 
organisati
on
WHO 
announces 
vaccine 
composition
February
July / 
August
Egg 
fertilization & 
incubation 
(11d)
Virus 
injection & 
incubation 
(3d)
Harvest of 
crude virus 
stocks
Inactivation, 
filtration, 
concentration
Formulation, 
filling, 
delivery
Faster and more flexible production methods are needed
As yet only 
feasible in winter 
due to higher 
bioburden in 
summer months
Long
planning
cycles
Low 
flexibility
Egg
contaminants
Suboptimal
antigen
match
Drawbacks
Source: DataMonitor 2007
8Performance of TIV (2007-2008)
Interim results for case-control study to estimate vaccine effectiveness 
for the prevention of medically attended, laboratory-confirmed influenza 
(MMWR, April 18, 2008)
Patients tested Positive 
for Influenza (N=191)1
Patients tested Negative 
for Influenza (N=425) Adjusted 
VE
% (95% CI)Vaccinate
d
Not 
Vaccinated
Vaccinate
d
Not 
Vaccinated
All influenza
All enrollees 36 155 165 260 44* (11, 65)
ACIP 
Recommended2 21 39 120 114 34 (-31, 67)
Healthy 
individuals 5-493 15 116 45 146 54* (12, 76)
1.By RT-PCR
2.Children 6-59 months; adults ≥50 y and adults 5-49 with chronic medical conditions
3.Persons 5-49 years without chronic medical conditions
*Statistically significant
9Approaches to Improve Vaccine Performance
? Increase the number of doses
? Increase hemagglutinin content
? Use of an adjuvant
? Vary type of preparation (whole virus, 
subvirion versus sub-unit)
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Manufacturing alternatives: cell culture-
based expression systems
MDCK Vero Per.C6 SF9
Origin Madin Darby Canine 
Kidney
African green monkey 
kidney
Human embryonic 
retina
Spodoptera frugiperda
Relative yield High Low Moderate Very high
Tumorigenicity High Not demonstrated Weak None
Other uses Veterinary vaccines Other human vaccines, 
e.g. poliovirus 
vaccines, rabies 
vaccines
Other human vaccines, 
antibodies, gene 
therapy, therapeutic 
proteins
Established protein 
expression system
Key advantage High viral yield Proven track record, 
has been used in 
production of other 
human vaccines
High susceptibility to 
influenza virus
High yield, high 
scaleability, low costs
Key 
disadvantage
High tumorigenicity Low virus yield Unclear benefits, 
newcomer
Immunogenicity 
perceived as low
Companies 
involved
NovartisVaccines, Solvay, 
GlaxoSmithKline
Baxter Crucell, Sanofi-Pasteur Protein Sciences
MDCK cells are furthest advanced and most popular approach
Source: DataMonitor 2007
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FluBlok:
rHA produced in insect cells
FluBlok® Approval → Validation
? Engineer baculovirus with the 
gene of interest (e.g. 
Hemagglutinin)
? Baculoviruses highly specific 
to insect cells
? Powerful promoter generates 
high yield of protein of 
interest
? Culture expression of 
insect cells in a 
fermenter
? Infect cells with 
engineered virus
? Incubate infection for ~48 
- 72 hours
? Protein forms rosettes
? Purify protein to > 90% 
into final product
? Formulate with PBS into 
vaccine
Baculovirus Expression Vector System (BEVS)
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Technology Improvements
SF+ Serum-free Cells
? Evolved from Sf9 Cells
? Selective pressure in serum-free media 
with added insulin (0.4 mM)
? unique phenotypic and genotypic 
properties
? Ideal for Manufacturing
? serum-free
? stable for > 50 passages
? infected with low MOI < 1
? produces high titer AcNPV
? cGMP at 500L scale
? excellent safety record in Phase I and 
Phase II clinical trials
? patent
? available for commercial and non-
commercial use
Uninfected SF+
Infected SF+
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SF+ Cell Growth and Infection
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Exponential
Growth
Efficient
Infection
• Cell growth and 
infection not limited by 
nutrients, waste, or O2
• Might be limited by 
autocrine factors
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HA yields: Feed’s Importance
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Hemagglutinin properties
? Trimeric integral membrane protein
? Cleavage of HA with host protease into HA1 and HA2 needed 
for fusion activity
? HA1 and HA2 linked by disulfide bonds
? Contains four antigenic sites (A, B, C, and D)
? Contains many glycosylation sites
? Hydrophobic transmembrane domain
A1C1 A2 B1B2 D C2Antigenic
Sites
COOH
s-s
s-s s-ss-s
s-s
HA1 HA2
Signal
Peptide
NH2 Arg
CHO CHO
CHOCHOCHOCHO CHO
Cytoplasmic
Domain
Transmembrane
Domain
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Fermentation Harvest Extraction
Purification
1. seed
Capture DNA removalPurify
Downstream Process
2. infect Disk-stack
centrifugation
TFF/Formulation
Clarification
Disk-stack
centrifugation
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FluBlok: Potential Benefits
(contains 3x45µg recombinant hemagglutinin)
? Influenza rHA antigens are produced in insect cells – protein based 
vaccine with low endotoxin content
? rHA protein is highly purified and does not contain egg protein or other 
contaminants from eggs 
? Selection or adaptation of influenza virus strains that produce at  high 
levels in eggs is not required =>the best genetic match 
? Cloning, expression and manufacture of FluBlok within 2 months
? FluBlok does not require large amounts of embryonated chicken eggs
? Manufacturing of FluBlok does not require biocontainment facilities
? Manufacture of rHA does not include formalin inactivation or organic 
extraction procedures
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Clinical Studies to Support BLA under accelerated 
approval mechanism
BLA filing to support licensure April 2008
? PSC01: Efficacy Study in Healthy Adults (451 subjects; 1:1:1)
? Placebo controlled and two doses of FluBlok
? PSC03: Efficacy Study in Adults older than 65y (869 subjects; 1:1)
? Active controlled study (FluZone®)
? PSC04: Field Efficacy Study in Healthy Adults (4650 subjects; 1:1)
(Interim Day 28 Safety and Immunogenicity available)
? Placebo controlled
? PSC06: Non-inferiority Immunogenicity/Efficacy Study in 600 Healthy 
Adults (50-64y)
(Interim Day 28 Safety and Immunogenicity available)
? Active controlled study (FluZone®)
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Clinical studies of rHA vaccines conducted 
under BB-IND 11951
 
Study  
Age Range 
 
Strain, Dose of rHA0 
N1 at 
135µg 
Dose  
(3 x 45µg) 
 
Control 
PSC01 
18-49 yr 
(2004-2005 
influenza season) 
45µg A/New Caledonia/20/1999 (H1N1) 
45µg A/Wyoming/3/03 (H3N2) 
45µg B/Jiangsu/10/03  
(Also 15µg H1 & B, 45µg H3) (N=151) 
 
153 
 
Saline 
(N=154) 
PSC03 
≥65 yr 
(2006-2007 
influenza season)  
 
45µg A/New Caledonia/20/1999 (H1N1) 
45µg A/Wisconsin/67/2005 (H3N2) 
45µg B/Ohio/1/2005 
 
436 
 
 
Fluzone 
(N=433) 
PSC04 
18-49 yr 
 (2007-2008 
influenza season) 
 
45µg A/Solomon Islands/3/2006 (H1N1) 
45µg A/Wisconsin/67/2005 (H3N2) 
45µg B/Malaysia/2506/2004 
 
2344 
 
Saline 
(N=2304) 
PSC06 
50-64 yr 
 (2007-2008 
influenza season) 
 
45µg A/Solomon Islands/3/2006 (H1N1) 
45µg A/Wisconsin/67/2005 (H3N2) 
45µg B/Malaysia/2506/2004 
 
300 
 
Fluzone 
(N=302) 
Total Safety 
Database ≥18 yr 
  
3233 
 
3193 
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Solicited Adverse Events in Adults During the 
First 7 Days After Administration of FluBlok, 
Placebo, or Comparator Influenza Vaccine
 Study PSC01 Study PSC04 Study PSC06 Study PSC03 
 Adults age 18-49 yrs Adults age 18-49 yrs Adults age 50-64 yrs Adults age ≥65 yrs 
 FluBlok* Placebo FluBlok Placebo FluBlok Fluzone FluBlok Fluzone 
Number of 
Subjects 153 154 2344 2304 300 302 436 433 
Local Adverse Events 
Pain  61% 17% 37% 8% 51% 55% 22% 23% 
Redness  5% 2% 4% 2% 8% 8% 10% 12% 
Swelling  10% 3% 3% 2% 8% 10% 11% 13% 
Bruising 7% 4% 3% 3% 5% 5% 3% 5% 
Systemic Adverse Events 
Headache  42% 41% 15% 15% 20% 21% 11% 9% 
Fatigue  16% 18% 15% 14% 13% 21% 9% 10% 
Muscle 
Pain 
20% 12% 10% 7% 13% 14% 7% 9% 
Fever‡ 0% 2% <1% <1% <1% 0 <1% 0% 
Joint pain  5% 5% 4% 4% 5% 6% 5% 6% 
Nausea  8% 6% 6% 5% 4% 5% 4% 3% 
Chills  3% 2% 3% 3% 4% 5% 4% 4% 
Sweating  3% 5% NA NA NA NA 3% 2% 
 
NOTE: Subjects are only counted once based on the most severe response reported by subjects on the memory aid.  
Results >1% reported to nearest whole percent; results >0 but <1 reported as <1%. 
* Data restricted to 135µg formulation.
† NA=data not available (not collected during the study).
‡ Fever defined as ≥99.8°F (37.7°C). In PSC03, fever was defined as >100.4°F. 
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PSC01 - FluBlok Phase II/III Field Study 
Summary of Results
Efficacy
? In PSC01, commercial dose level (135µg total rHA) provided: 
? 100% (95% CI: 29.7, 100) efficacy against culture 
confirmed CDC-ILI
? 87.3% (95% CI: 5.5, 99.7) efficacy against culture 
confirmed respiratory illness (CDC-ILI not required)
? 54.4% reduction in CDC-ILI (regardless of culture results)
? Lower dose level (75µg total rHA: 15µg H1 15µg B, 45µg H3 ) not 
selected for further development also demonstrated 71% 
“protective efficacy” and 30% reduction in CDC-ILI vs. placebo
? Significant dose response effect confirmed for H1 and B
Highly 
Immunogenic
? Protective levels for all antigens for at least 6 months
? H3 component – high and sustained immunogenicity and long 
lasting titers 
Protection 
Against Drifted 
Strains
? Excellent protection against viruses that had changed (drifted 
strains included in efficacy estimates provided above)
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PSC01 - Results Published In JAMA
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PSC03: Difference in Proportions of Subjects with 
Seroconversion or Significant Increase in HI Titers at 
Day 28 
CBER Criterion 
for non-inferiority: 
lower bound of 
the two-sided 
95% CI for the % 
of subjects 
achieving 
seroconversion 
should meet or 
exceed 30%.” 
ALL SUBJECTS 
 
SUBJECTS ≥75 
FluBlok 
N=431 
Fluzone 
N=430 
FluBlok 
N=163 
Fluzone 
N=159 
 
 
 
STRAINS 
Number Of Subjects (%) [95% CI] 
A/New Caledonia 
Seroconversion1 or 
significant increase2 
      [2-sided 95% CI] 
187 (43) 
[38.7, 48.2] 
140 (33) 
[28.1*, 37.2] 
64 (39) 
[31.8, 46.8] 
48 (30) 
[23.1, 37.3] 
Difference in 
proportions between 
TIV and FluBlok 
 
-10.8 
 
-9.1 
      2-sided 95% CI -17.3, -4.3 -19.4, 1.3 
     P-Value3 0.001 0.087 
Meets CBER criterion for 
non-inferiority? ‡ 
YES YES 
A/Wisconsin 
Seroconversion1 or 
significant increase2 
     [2-sided 95% CI] 
335 (78) 
 [73.5, 81.6] 
248 (58) 
 [52.8, 62.4] 
129 (79) 
 [72.9, 85.4] 
86 (54) 
 [46.3, 61.8] 
Difference in 
proportions between 
TIV and FluBlok 
 
-20.1 
 
-25.1 
     2-sided 95% CI -26.2, -13.9 -35.0, -15.1 
      P-Value <0.001 <0.001 
Meets CBER criterion for 
non-inferiority? ‡ 
YES YES 
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PSC03 -continued
CBER Criterion for a non-inferiority: the upper bound of 
the two-sided 95% CI on the ratio of the GMT’s does not 
exceed 1.5. This criterion is met for FluBlok for all 
antigens
A/New Caledonia (H1) A/Wisconsin (H3) 
Timepoint 
 
 
Vaccine Group GMT 95% CI GMT 95% CI 
Day 0 Fluzone (N=430) 70.2 (62.8, 78.6) 44.7 (39.2, 51.0) 
 FluBlok (N=431) 69.0 (62.1, 76.6) 42.7 (37.6, 48.4) 
Day 28  Fluzone (N=430) 148.1 (134.2, 163. 4) 199.2 (176.8, 224.4) 
 FluBlok (N=431) 176.8 (159.4, 196.0) 338.5 (299.7, 382.5) 
 Ratio GMT TIV/FluBlok 0.84 (0.81, 0.86) 0.59 (0.57, 0.60) 
 
Meets CBER 
Criterion? YES  YES  
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CBER Guidance to Support Accelerated Approval in 
Placebo Controlled Trial 
? The lower bound of the two-sided 95% CI for the percent of the subjects achieving 
seroconversion for HI antibody should meet or exceed 40%
? The lower bound of the two-sided 95% CI for the percent of the subjects achieving an 
HI Antibody titer ≥40 should meet or exceed 70%
Strains Titer ≥40 95% CI Seroconverted* 95% CI
H1N1
A/Solomon Island/3/2006
98% 97.2, 99.7 78% 74.2, 82.3
H3N2
A/Wisconsin/67/2005
96% 94.6, 98.3 81% 76.6, 84.5
B
B/Malaysia/2506/2004
96% 93.9, 97.9 53% 48.3, 58.1
* ≥4-fold increase and minimum titer 40
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PSC06 - Field Study - Serology Results 
FluBlok (135µg)
?Total enrolled 602 subject (50-64 y) at 6 centers
?Average age: 56 years; 63% female
?HAI Titers were determined 
?Data used to support accelerated approval in the US
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CBER Guidance to Support Accelerated Approval 
Applied to PSC06
 No. of Subjects (%) 
 FluBlok  
(N=299) 
Fluzone 
(N=302) 
A/Solomon Islands/03/06 
Seroconversion1 or Significant 
Increase2 
  
   Yes 216 (72) 200 (66) 
   2-sided 95% CI [66.8, 77.2] [60.6, 71.5] 
   Meets CBER criterion?3 YES YES 
 
Difference in Proportions (TIV vs 
FluBlok) 
-6.0 
   2-sided 95% CI [-13.4, 1.4] 
   P-value 0.113 
   Meets CBER criterion?4 YES 
B/Malaysia/2506/04  
Seroconversion1 or Significant 
Increase2 
  
   Yes 122 (41) 124 (41) 
   2-sided 95% CI [35.2, 46.6] [35.5, 46.8] 
   Meets CBER criterion?3 NO NO 
 
Difference in Proportions (TIV vs 
FluBlok) 
0.3 
   2-sided 95% CI [-7.7, 8.2] 
   P-value 1.000 
   Meets CBER criterion?4 YES 
A/Wisconsin/67/05 
Seroconversion1 or Significant 
Increase2 
  
   Yes 183 (61) 132 (44) 
   2-sided 95% CI [55.4, 66.8] [38.0, 49.5] 
   Meets CBER criterion?3 YES NO 
 
Difference in Proportions (TIV vs 
FluBlok) 
-17.5 
   2-sided 95% CI [-25.4, -9.5] 
   P-value <0.001 
   Meets CBER criterion?4 YES 
 
1 4-fold or greater increase from pre-
vaccination to Day 28 with a 
minimum Day 28 titer of 1:40.
2 Pre-vaccination titer below limit of 
detection and Day 28 titer ≥1:40.
3 Lower bound of 2-sided 95% CI 
should meet or exceed 40% (for 
persons <age 65 years)
4 Upper bound of 2-sided 95% CI on 
the difference between 
seroconversion rates should not 
exceed 10%CI based on Clopper-
Pearson exact method; P-value 
based on Fisher’s Exact Test
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CBER Guidance to Support Accelerated Approval 
Applied to PSC06
 
 
 
  A/Solomon 
Islands/03/06 
A/Wisconsin/67/05 B/Malaysia/2506/04 
Visit Dose Group N GMT 95% CI GMT 95% CI GMT 95% CI 
Day 0 FluBlok 299 28.71 (25.59, 32.21) 18.57 (16.37, 21.06) 48.49 (43.38, 54.19)
 Fluzone 302 27.77 (25.07, 30.76) 18.20 (16.07, 20.62) 49.18 (43.77, 55.25)
 
Day 28  FluBlok 299 181.34 (159.61, 206.02) 105.41 (91.01, 122.09) 110.93 (100.07, 122.97)
 Fluzone 302 139.74 (124.64, 156.66) 60.88 (53.58, 69.18) 116.03 (104.16, 129.25)
 
Ratio of GMT1 at Day 28 0.77 (0.75, 0.79)  0.58  (0.53, 0.62)  1.05 (1.01, 1.09)  
   Meets CBER criterion?  YES  YES  YES 
1 Ratio of GMT=(GMT TIV/GMT FluBlok) 
Ratio should be lower than 1.5
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FluBlok Manufacturing
? Launch of FluBlok in house
? 2008 - 600-L (1-2 million doses)
? 2009 – 1,800L (5-10 million doses)
? 2010+ 
? 2 x 5000L in new facility in Meriden (up to 60 million doses); or
? LSM outsource
30
Outlook – 2008 and beyond
? FluBlok to market
? BLA Filing April, 2008
? Approval anticipated in time for 2008/09 flu season
? PSC04 and PSC06
? Safety and antibody titers submitted
? Field data – Q3/Q4
? Tentative FDA approval date –October 2008
